Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02012114
Other study ID # 2010-605
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date December 2011
Est. completion date December 14, 2021

Study information

Verified date May 2022
Source Hospices Civils de Lyon
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Preventing late onset of Cystinosis such as neurological complications and improving compliance to cysteamine treatment remain major challenges in management of subjects with cystinosis. This study is designed to describe the relationship between compliance of patients with cystinosis treated with cysteamine and treatment efficacy and to understand the pathophysiologic mechanism of neurological disorders. Is cysteamine crossing the blood brain barrier? What is the impact of cystine accumulation in Cerebro Spinal Fluid and Central Nervous System? Our Primary objective is to study the relationship between compliance of patients treated with cysteamine and the WBC cystine level. Secondary, the study will assess relationship between compliance to cysteamine and its neurological consequences. The expected duration of the study is 48 months. The enrolment period is 24 months and the study participation of each subject is 24 months. Eligible participants are male and female (age > 4 years) with confirmed diagnosis of cystinosis and receiving any oral cysteamine treatment: Cystagon or RP103. The compliance under cysteamine is measured using electronic devices, accountability of study treatment, and information in patients' diary. Specific memory and visuoperceptual tests are performed at the beginning and at the end of patients'participation. Nuclear Magnetic Resonance spectroscopy is used to detect possible sites of cystine accumulation in the CNS and their relationship with compliance to cysteamine treatment. NMRS is also used to establish a relationship with the neuropsychological status of the subject. To describe absorption, distribution and elimination of cysteamine, and its metabolic pathways, and to determine the concentration effect and dose effect relationship, blood samples are performed at each study visit. A lumbar puncture is also proposed to participants to verify if cysteamine is crossing the blood brain barrier. New tools are used to compare metabonomic networks in patients with cystinosis and their controls.


Recruitment information / eligibility

Status Completed
Enrollment 65
Est. completion date December 14, 2021
Est. primary completion date December 5, 2016
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 4 Years and older
Eligibility - Male and female subjects with confirmed diagnosis of nephropathic cystinosis (defined by clinical signs and WBC cystine level). - Age > 4 years. - Subjects receiving any oral cysteamine treatment: Cystagon or RP103. - Sexually active female subjects of childbearing potential must agree to utilize the same acceptable form of contraception from day 1 through completion of the study. - Subjects or their parent or legal guardian must provide written informed consent prior to participation in the study. - Subjects covered by or having the right to social security. Exclusion Criteria: - Subjects with known hypersensitivity to cysteamine and penicillamine. - Females who are nursing, planning a pregnancy, known or suspected to be pregnant, or with a positive urinary pregnancy test. - Subjects who, in the opinion of the Investigator, are not able or willing to comply with the protocol. - Contra-indication to MRI assessment CONTROLS FOR METABONOMIC ASSESSMENTS Inclusion Criteria: - Age and sex matched to study population: Age range: patients aged 4 to 5 years, 6 to 11 years, patients aged 12 to 17 years, adult patients: 18 or above. Sex: male or female - Subjects or their parent or legal guardian must provide written informed consent prior to participation in the study. - Subjects covered by or having the right to social security. Exclusion Criteria: - Any uropathology or nephropathology. CONTROLS FOR NMRS ASSESSMENTS Inclusion Criteria: - Age and sex matched to study population: Age range: patients aged 4 to 5 years, 6 to 11 years, patients aged 12 to 17 years, adult patients: 18 or above. Sex: male or female - Subjects or their parent or legal guardian must provide written informed consent prior to participation in the study. - Subjects covered by or having the right to social security. Exclusion Criteria: - Any uropathology or nephropathology. - Any neurological and/or psychiatric disorder - Contra-indication to MRI assessment.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Cysteamine bitartrate
No intervention

Locations

Country Name City State
France Hospices Civils de Lyon Lyon

Sponsors (1)

Lead Sponsor Collaborator
Hospices Civils de Lyon

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary WBC cystine levels PD measurements will be performed at D1, M1, M3, M6, M9, M12, M15, M18, M21 and M24.
Compliance under cysteamine will be measured from D1 to M24 using electronic devices (date and time of bottle opening are recorded), accountability of study treatment and information of patients' diary. Compliance measurement between two consecutive study visits will be expressed as the proportion of the observed number of opening compared to the expected number and the cumulated dose taken compared to the expected dose.Compliance will be first considered as a dichotomous variable, the compliance being described as satisfactory if greater than 95% during a specific period.Compliance will then be considered as a quantitative variable
Day1and every three months : Month1, Month3, Month6, Month9, Month12, Month15, Month18, Month21 and Month24.
Secondary Presence or absence and accountability of cystine crystals. Eye examination Every 6 month : Month1, Month6, Month12, Month18, Month24
Secondary Memory and visuoperceptual tests repeated during the study at Day 1 and two years
Secondary presence or absence of cystine accumulation, determination of the sites of cystine accumulation in the CNS and relationship with the compliance to cysteamine treatment, relationship with neuropsychological status. NMRS assessments at Month 1 and two years
Secondary Concentration of cysteamine in the CSF, associated to a measurement of the CSF pressure at any visit
Secondary concentration of cysteamine in blood (measured by toxicological HPLC analysis with fluorescence detection) at Day1 and every 3 months : month1, month3, month6, month9, month12, month15, month18, month21, month24
Secondary discrimination of urine and blood samples,from metabolic spectroscopic data obtained by nuclear magnetic resonance. Perturbed metabolic network resulting from the intake of cysteamine in comparison to controls,using urine and blood samples available for patients with cystinosis and their controls Every 3 months during 6 months and every 6 months to month 6 until two years
Secondary Concentration effect, dose effect model. pharmacokinetic profile and 2 timepoints pharmacodynamics. at month 6
See also
  Status Clinical Trial Phase
Recruiting NCT05545774 - Neuromuscular Characterisation in Late Adolescent and Adult Cystinosis Patients
Completed NCT01432561 - Study in Healthy Adults to Determine the Effect That Food Has on the Absorption and Delivery of the Drug Cystagonâ„¢ N/A
Recruiting NCT05687474 - Baby Detect : Genomic Newborn Screening
Completed NCT04125927 - Cystadrops in Pediatric Cystinosis Patients From Six Months to Less Than Two Years Old (SCOB2) Phase 3
Completed NCT00071903 - The Role of Susceptibility to Thrombosis in the Pseudotumor Cerebri of Nephropathic Cystinosis: A Case-Control Study N/A
Recruiting NCT05994534 - PK and PD Study of NPI-001 and Cysteamine Bitartrate Phase 1/Phase 2
Completed NCT00004350 - Evaluation of Fanconi Syndrome and Cystinosis N/A
Completed NCT00004312 - Establishment of a Database for Long-Term Monitoring of Patients With Nephropathic Cystinosis N/A
Enrolling by invitation NCT03655223 - Early Check: Expanded Screening in Newborns
Recruiting NCT06065852 - National Registry of Rare Kidney Diseases
Completed NCT02533076 - The Functional Consequences of the CTNS-deletion for the TRPV1-receptor in Cystinosis Patients Phase 0
Enrolling by invitation NCT05146830 - A Long-Term Follow-Up Study of Participants With Cystinosis Who Previously Received CTNS-RD-04
Completed NCT00872729 - Pilot Study of Safety, Tolerability, Pharmacokinetics/Pharmacodynamics of RP103 Compared to Cystagon® in Patients With Cystinosis Phase 1/Phase 2
Completed NCT00001736 - New Cysteamine Eye Drops Formulation to Treat Corneal Crystals in Cystinosis Phase 1
Recruiting NCT05959668 - Development of Health-related Quality of Life Instrument for Patients With Cystinosis
Withdrawn NCT02124070 - Therapeutic Effect of Recombinant Human Growth Hormone (rhGH) on the Myopathy of Cystinosis Phase 1/Phase 2
Completed NCT01614431 - N Acetyl Cysteine for Cystinosis Patients Phase 4
Recruiting NCT05843851 - Genetic Newborn Screening for Cystinosis and Primary Hyperoxaluria N/A
Completed NCT01000961 - Phase 3 Study of Cysteamine Bitartrate Delayed-release (RP103) Compared to Cystagon® in Patients With Cystinosis Phase 3
Active, not recruiting NCT03897361 - Stem Cell Gene Therapy for Cystinosis Phase 1/Phase 2